If you experience any suspected side effects whilst participating in a retatrutide trial or after stopping treatment, these should be reported to the trial team and, where appropriate, via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk), which enables reporting of suspected adverse reactions to medicines and vaccines in the UK
However, with persistence, the right approach, and armed with evidence, its possible to secure coverage for these essential procedures
This category is moving far beyond appetite suppression
Your healing deserves more than basic aftercare
Compatible pharmacokinetics
Sometimes, this is often an individualised, clinician-led decision (and may be off-label depending on product/region), especially if pregnancy is planned